{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T04:28:09Z","timestamp":1789446489089,"version":"build-2803163510"},"reference-count":160,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Heart failure with preserved ejection fraction (HFpEF) is characterized by a notable heterogeneity in both phenotypic and pathophysiological features, with a growing incidence due to the increase in median age and comorbidities such as obesity, arterial hypertension, and cardiometabolic disease. In recent decades, the development of new pharmacological and non-pharmacological options has significantly impacted outcomes, improving clinical status and reducing mortality. Moreover, a more personalized and accurate therapeutic management has been demonstrated to enhance the quality of life, diminish hospitalizations, and improve overall survival. Therefore, assessing the peculiarities of patients with HFpEF is crucial in order to obtain a better understanding of this disorder. Importantly, comorbidities have been shown to influence symptoms and prognosis, and, consequently, they should be carefully addressed. In this sense, it is mandatory to join forces with a multidisciplinary team in order to achieve high-quality care. However, HFpEF remains largely under-recognized and under-treated in clinical practice, and the diagnostic and therapeutic management of these patients remains challenging. The aim of this paper is to articulate a pragmatic approach for patients with HFpEF focusing on the etiology, diagnosis, and treatment of HFpEF.<\/jats:p>","DOI":"10.3390\/jcm13051375","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T06:14:22Z","timestamp":1709100862000},"page":"1375","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Heart Failure with Preserved Ejection Fraction: How to Deal with This Chameleon"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5369-5382","authenticated-orcid":false,"given":"Fabiana","family":"Luc\u00e0","sequence":"first","affiliation":[{"name":"Cardiology Department, Grande Ospedale Metropolitano, 89129 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Oliva","sequence":"additional","affiliation":[{"name":"Cardiology Department De Gasperis Cardio Center, Niguarda Hospital, 20162 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0237-7157","authenticated-orcid":false,"given":"Maurizio Giuseppe","family":"Abrignani","sequence":"additional","affiliation":[{"name":"Operative Unit of Cardiology, P. Borsellino Hospital, 91025 Marsala, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8586-9930","authenticated-orcid":false,"given":"Stefania Angela","family":"Di Fusco","sequence":"additional","affiliation":[{"name":"Cardiology Department, San Filippo Neri Hospital, ASL Roma 1, 00135 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Gori","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, Azienda Ospedaliera Papa Giovanni XXIII Hospital, 24127 Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Giubilato","sequence":"additional","affiliation":[{"name":"Cardiology Department, Ospedale Lamezia Terme, 88046 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Ceravolo","sequence":"additional","affiliation":[{"name":"Cardiac Rehabilitation Unitof Maugeri, IRCCS, 28010 Gattico-Veruno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6220-2471","authenticated-orcid":false,"given":"Pier Luigi","family":"Temporelli","sequence":"additional","affiliation":[{"name":"Cardiology Department, Cannizzaro Hospital, 95126 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4311-2139","authenticated-orcid":false,"given":"Stefano","family":"Cornara","sequence":"additional","affiliation":[{"name":"Arrhytmia Unit, Division of Cardiology, Ospedale San Paolo, Azienda Sanitaria Locale 2, 17100 Savona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo Massimiliano","family":"Rao","sequence":"additional","affiliation":[{"name":"Cardiology Department, Grande Ospedale Metropolitano, 89129 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Caretta","sequence":"additional","affiliation":[{"name":"Levante Ligure Sant\u2019Andrea Hospital, ASL 5 Liguria, 19121 La Spezia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9819-2148","authenticated-orcid":false,"given":"Andrea","family":"Pozzi","sequence":"additional","affiliation":[{"name":"Cardiology Division, Valduce Hospital, 22100 Como, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Binaghi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Azienda Ospedaliera Brotzu, 09134 Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2612-6264","authenticated-orcid":false,"given":"Alessandro","family":"Maloberti","sequence":"additional","affiliation":[{"name":"Cardiology Department De Gasperis Cardio Center, Niguarda Hospital, 20162 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8925-6149","authenticated-orcid":false,"given":"Concetta","family":"Di Nora","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic Science, Azienda Sanitaria UniversitariaIntegrata di Udine, 33100 Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Di Matteo","sequence":"additional","affiliation":[{"name":"Cardiology Department De Gasperis Cardio Center, Niguarda Hospital, 20162 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pilleri","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Azienda Ospedaliera Brotzu, 09134 Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7746-989X","authenticated-orcid":false,"given":"Sandro","family":"Gelsomino","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Institute, Maastricht University, 6229 HX Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Riccio","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, Sant\u2019Anna e San Sebastiano Hospital, 81100 Caserta, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-8884","authenticated-orcid":false,"given":"Massimo","family":"Grimaldi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, General Regional Hospital \u201cF. Miulli\u201d, 70021 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furio","family":"Colivicchi","sequence":"additional","affiliation":[{"name":"Cardiology Department, San Filippo Neri Hospital, ASL Roma 1, 00135 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele Massimo","family":"Gulizia","sequence":"additional","affiliation":[{"name":"Cardiology Department, Garibaldi Nesima Hospital, 95122 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41569-020-0363-2","article-title":"Evaluation and management of heart failure with preserved ejection fraction","volume":"17","author":"Borlaug","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","article-title":"2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure with Preserved Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jchf.2023.03.011","article-title":"How to Manage Heart Failure with Preserved Ejection Fraction","volume":"11","author":"Desai","year":"2023","journal-title":"JACC Heart Fail."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Stoicescu, L., Cri\u015fan, D., Morgovan, C., Avram, L., and Ghibu, S. (2024). Heart Failure with Preserved Ejection Fraction: The Pathophysiological Mechanisms behind the Clinical Phenotypes and the Therapeutic Approach. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25020794"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/nrcardio.2013.30","article-title":"The roles of senescence and telomere shortening in cardiovascular disease","volume":"10","author":"Fyhrquist","year":"2013","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nrm2233","article-title":"Cellular senescence: When bad things happen to good cells","volume":"8","author":"Campisi","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1001\/jamacardio.2017.4987","article-title":"Association of Cardiovascular Biomarkers with Incident Heart Failure with Preserved and Reduced Ejection Fraction","volume":"3","author":"Nayor","year":"2018","journal-title":"JAMA Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jacc.2019.05.052","article-title":"Age-Related Characteristics and Outcomes of Patients with Heart Failure with Preserved Ejection Fraction","volume":"74","author":"Tromp","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ccl.2022.06.006","article-title":"Geriatric Domains in Patients with Heart Failure with Preserved Ejection Fraction","volume":"40","author":"Goyal","year":"2022","journal-title":"Cardiol. Clin."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.cardfail.2023.10.346","article-title":"Targeted Geriatric Assessment In Heart Failure with Preserved Ejection Fraction","volume":"30","author":"Pieroni","year":"2024","journal-title":"J. Card. Fail."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: The HFA-PEFF diagnostic algorithm: A consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Luc\u00e0, F., Abrignani, M.G., Parrini, I., Di Fusco, S.A., Giubilato, S., Rao, C.M., Piccioni, L., Cipolletta, L., Passaretti, B., and Giallauria, F. (2022). Update on Management of Cardiovascular Diseases in Women. J. Clin. Med., 11.","DOI":"10.3390\/jcm11051176"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Iorio, A., Luc\u00e0, F., Pozzi, A., Rao, C.M., Chimenti, C., Di Fusco, S.A., Rossini, R., Caretta, G., Cornara, S., and Giubilato, S. (2024). Anderson-Fabry Disease: Red Flags for Early Diagnosis of Cardiac Involvement. Diagnostics, 14.","DOI":"10.3390\/diagnostics14020208"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1161\/CIRCULATIONAHA.118.035711","article-title":"H(2)FPEF Score: At Last, a Properly Validated Diagnostic Algorithm for Heart Failure with Preserved Ejection Fraction","volume":"138","author":"Paulus","year":"2018","journal-title":"Circulation"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.mri.2020.11.011","article-title":"Cardiac MRI for the prognostication of heart failure with preserved ejection fraction: A systematic review and meta-analysis","volume":"76","author":"Assadi","year":"2021","journal-title":"Magn. Reson. Imaging"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1093\/eurheartj\/ehac121","article-title":"BNP: Biomarker Not Perfect in heart failure with preserved ejection fraction","volume":"43","author":"Shah","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1161\/CIRCULATIONAHA.117.028365","article-title":"Obese Heart Failure with Preserved Ejection Fraction Phenotype: From Pariah to Central Player","volume":"136","author":"Kitzman","year":"2017","journal-title":"Circulation"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ejhf.1494","article-title":"Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations","volume":"21","author":"Mueller","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1093\/eurheartj\/ehab911","article-title":"Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality","volume":"43","author":"Verbrugge","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1161\/CIRCULATIONAHA.118.034646","article-title":"A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure with Preserved Ejection Fraction","volume":"138","author":"Reddy","year":"2018","journal-title":"Circulation"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e005312","DOI":"10.1161\/CIRCHEARTFAILURE.118.005312","article-title":"Cardiac Troponin I and Risk of Cardiac Events in Patients with Heart Failure and Preserved Ejection Fraction","volume":"11","author":"Myhre","year":"2018","journal-title":"Circ. Heart Fail."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamacardio.2016.4726","article-title":"Factors Associated with and Prognostic Implications of Cardiac Troponin Elevation in Decompensated Heart Failure with Preserved Ejection Fraction: Findings from the American Heart Association Get with The Guidelines-Heart Failure Program","volume":"2","author":"Pandey","year":"2017","journal-title":"JAMA Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/ehf2.12203","article-title":"Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis","volume":"5","author":"Takashio","year":"2018","journal-title":"ESC Heart Fail."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1002\/ejhf.2607","article-title":"Biomarker-driven prognostic models in chronic heart failure with preserved ejection fraction: The EMPEROR-Preserved trial","volume":"24","author":"Pocock","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"ref_27","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa020245","article-title":"Obesity and the risk of heart failure","volume":"347","author":"Kenchaiah","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.jchf.2018.05.018","article-title":"The Association of Obesity and Cardiometabolic Traits with Incident HFpEF and HFrEF","volume":"6","author":"Savji","year":"2018","journal-title":"JACC Heart Fail."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure with Preserved Ejection Fraction","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.pcad.2018.05.005","article-title":"Obesity and the Obesity Paradox in Heart Failure","volume":"61","author":"Horwich","year":"2018","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/s41366-020-0579-6","article-title":"Disparate effects of obesity on survival and hospitalizations in heart failure with preserved ejection fraction","volume":"44","author":"Carbone","year":"2020","journal-title":"Int. J. Obes."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1161\/CIRCULATIONAHA.115.016801","article-title":"Body Mass Index, Abdominal Fatness, and Heart Failure Incidence and Mortality: A Systematic Review and Dose-Response Meta-Analysis of Prospective Studies","volume":"133","author":"Aune","year":"2016","journal-title":"Circulation"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"558271","DOI":"10.3389\/fendo.2020.558271","article-title":"Sarcopenic Obesity in Heart Failure with Preserved Ejection Fraction","volume":"11","author":"Kirkman","year":"2020","journal-title":"Front. Endocrinol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1001\/jama.2015.17346","article-title":"Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients with Heart Failure with Preserved Ejection Fraction: A Randomized Clinical Trial","volume":"315","author":"Kitzman","year":"2016","journal-title":"JAMA"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s11695-013-0953-8","article-title":"Impact of bariatric surgery on quality of life, functional capacity, and symptoms in patients with heart failure","volume":"23","author":"Miranda","year":"2013","journal-title":"Obes. Surg."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1161\/CIRCRESAHA.119.313572","article-title":"Heart Failure with Preserved Ejection Fraction In Perspective","volume":"124","author":"Pfeffer","year":"2019","journal-title":"Circ. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jchf.2015.12.003","article-title":"Temporal Trends of Digoxin Use in Patients Hospitalized with Heart Failure: Analysis from the American Heart Association Get with The Guidelines-Heart Failure Registry","volume":"4","author":"Patel","year":"2016","journal-title":"JACC Heart Fail."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/eurheartj\/ehn153","article-title":"Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme","volume":"29","author":"MacDonald","year":"2008","journal-title":"Eur. Heart J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/ejhf.1149","article-title":"Heart failure with mid-range ejection fraction in CHARM: Characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum","volume":"20","author":"Lund","year":"2018","journal-title":"Eur. J. Heart Fail."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.amjcard.2009.09.041","article-title":"Comparison of patients with heart failure and preserved left ventricular ejection fraction among those with versus without diabetes mellitus","volume":"105","author":"Aguilar","year":"2010","journal-title":"Am. J. Cardiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/CIRCULATIONAHA.116.024593","article-title":"Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients with Heart Failure and Preserved Ejection Fraction: A Report from the I-Preserve Trial (Irbesartan in Heart Failure with Preserved Ejection Fraction)","volume":"135","author":"Kristensen","year":"2017","journal-title":"Circulation"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jacc.2014.05.030","article-title":"Cardiovascular phenotype in HFpEF patients with or without diabetes: A RELAX trial ancillary study","volume":"64","author":"Lindman","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.jacc.2018.11.033","article-title":"Heart Failure with Preserved Ejection Fraction and Diabetes: JACC State-of-the-Art Review","volume":"73","author":"McHugh","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"d4169","DOI":"10.1136\/bmj.d4169","article-title":"Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: Meta-analysis of randomised controlled trials","volume":"343","author":"Boussageon","year":"2011","journal-title":"BMJ"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 Inhibitors with Cardiovascular and Kidney Outcomes in Patients with Type 2 Diabetes: A Meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12933-022-01545-1","article-title":"Effects of sacubitril\/valsartan on glycemia in patients with diabetes and heart failure: The PARAGON-HF and PARADIGM-HF trials","volume":"21","author":"Wijkman","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/ejhf.1818","article-title":"Trends in prevalence of comorbidities in heart failure clinical trials","volume":"22","author":"Khan","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/heartjnl-2022-321097","article-title":"Management of patients with heart failure and preserved ejection fraction","volume":"109","author":"Campbell","year":"2023","journal-title":"Heart"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1097\/HJH.0000000000002910","article-title":"Hypertension and heart failure with preserved ejection fraction: Position paper by the European Society of Hypertension","volume":"39","author":"Kasiakogias","year":"2021","journal-title":"J. Hypertens."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.jacc.2020.06.069","article-title":"Pulmonary Hypertension in HFpEF and HFrEF: JACC Review Topic of the Week","volume":"76","author":"Guazzi","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1016\/j.chest.2021.08.039","article-title":"Pulmonary Hypertension in the Context of Heart Failure with Preserved Ejection Fraction","volume":"160","author":"Inampudi","year":"2021","journal-title":"Chest"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jjcc.2019.01.005","article-title":"Prognostic impact of chronic obstructive pulmonary disease on adverse prognosis in hospitalized heart failure patients with preserved ejection fraction\u2014A report from the JASPER registry","volume":"73","author":"Sato","year":"2019","journal-title":"J. Cardiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e021494","DOI":"10.1161\/JAHA.121.021494","article-title":"Impact of Chronic Obstructive Pulmonary Disease in Patients with Heart Failure with Preserved Ejection Fraction: Insights from PARAGON-HF","volume":"10","author":"Mooney","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.amjcard.2021.03.009","article-title":"Impact of Chronic Obstructive Pulmonary Disease in Heart Failure with Preserved Ejection Fraction","volume":"149","author":"Jain","year":"2021","journal-title":"Am. J. Cardiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/eurjhf\/hfn013","article-title":"Heart failure and chronic obstructive pulmonary disease: Diagnostic pitfalls and epidemiology","volume":"11","author":"Hawkins","year":"2009","journal-title":"Eur. J. Heart Fail."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2300239","DOI":"10.1183\/13993003.00239-2023","article-title":"Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary","volume":"61","author":"Celli","year":"2023","journal-title":"Eur. Respir. J."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC Guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1002\/ejhf.3000","article-title":"Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVER","volume":"25","author":"Butt","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jchf.2015.09.014","article-title":"Prevalence and Predictors of Sleep-Disordered Breathing in Patients with Stable Chronic Heart Failure: The SchlaHF Registry","volume":"4","author":"Arzt","year":"2016","journal-title":"JACC Heart Fail."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Moula, A.I., Parrini, I., Tetta, C., Luc\u00e0, F., Parise, G., Rao, C.M., Mauro, E., Parise, O., Matteucci, F., and Gulizia, M.M. (2022). Obstructive sleep apnea and atrial fibrillation. J. Clin. Med., 11.","DOI":"10.3390\/jcm11051242"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1183\/09031936.00045609","article-title":"Adaptive servoventilation in diastolic heart failure and Cheyne-Stokes respiration","volume":"36","author":"Bitter","year":"2010","journal-title":"Eur. Respir. J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurjhf\/hfs197","article-title":"Impact of adaptive servo-ventilation on cardiovascular function and prognosis in heart failure patients with preserved left ventricular ejection fraction and sleep-disordered breathing","volume":"15","author":"Yoshihisa","year":"2013","journal-title":"Eur. J. Heart Fail."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/clc.22412","article-title":"Beneficial Effects of Positive Airway Pressure Therapy for Sleep-Disordered Breathing in Heart Failure Patients with Preserved Left Ventricular Ejection Fraction","volume":"38","author":"Yoshihisa","year":"2015","journal-title":"Clin. Cardiol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"69","DOI":"10.31083\/j.rcm2302069","article-title":"Interrelation between heart failure with preserved ejection fraction and renal impairment","volume":"23","author":"Joslin","year":"2022","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1093\/eurheartj\/ehac683","article-title":"Prevention of cardiorenal damage: Importance of albuminuria","volume":"44","author":"Ruilope","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s11739-019-02188-z","article-title":"Incidence and implications of acute kidney injury in patients hospitalized with acute decompensated heart failure","volume":"15","author":"Doshi","year":"2020","journal-title":"Intern. Emerg. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamacardio.2022.4210","article-title":"Dapagliflozin and Kidney Outcomes in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Randomized Clinical Trial","volume":"8","author":"Claggett","year":"2023","journal-title":"JAMA Cardiol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/ejhf.2857","article-title":"Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from the EMPEROR-Preserved trial","volume":"25","author":"Sharma","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1002\/jcsm.12483","article-title":"Sarcopenia: A Time for Action. An SCWD Position Paper","volume":"10","author":"Bauer","year":"2019","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jamda.2019.12.012","article-title":"Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment","volume":"21","author":"Chen","year":"2020","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/eurjpc\/zwaa117","article-title":"Impact of sarcopenia on prognosis in patients with heart failure with reduced and preserved ejection fraction","volume":"28","author":"Konishi","year":"2021","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/ggi.12210","article-title":"Using two different algorithms to determine the prevalence of sarcopenia","volume":"14","author":"Yoshida","year":"2014","journal-title":"Geriatr. Gerontol. Int."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1002\/ejhf.1304","article-title":"Comparison of sarcopenia and cachexia in men with chronic heart failure: Results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF)","volume":"20","author":"Emami","year":"2018","journal-title":"Eur. J. Heart Fail."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1002\/ejhf.1244","article-title":"Waist-to-hip ratio and mortality in heart failure","volume":"20","author":"Streng","year":"2018","journal-title":"Eur. J. Heart Fail."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/ehf2.12388","article-title":"Muscle wasting and sarcopenia in heart failure: A brief overview of the current literature","volume":"5","year":"2018","journal-title":"ESC Heart Fail."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/ajag.12521","article-title":"Exercise interventions in healthy older adults with sarcopenia: A systematic review and meta-analysis","volume":"37","author":"Vlietstra","year":"2018","journal-title":"Australas. J. Ageing"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1161\/CIRCHEARTFAILURE.114.001615","article-title":"Exercise training in patients with heart failure and preserved ejection fraction: Meta-analysis of randomized control trials","volume":"8","author":"Pandey","year":"2015","journal-title":"Circ. Heart Fail."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jacc.2012.02.055","article-title":"Effect of endurance training on the determinants of peak exercise oxygen consumption in elderly patients with stable compensated heart failure and preserved ejection fraction","volume":"60","author":"Haykowsky","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3945\/ajcn.116.143594","article-title":"Effects of protein supplementation combined with resistance exercise on body composition and physical function in older adults: A systematic review and meta-analysis","volume":"106","author":"Liao","year":"2017","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nrcardio.2017.51","article-title":"Muscle wasting and cachexia in heart failure: Mechanisms and therapies","volume":"14","author":"Ebner","year":"2017","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Pinter, A., Behon, A., Veres, B., Merkel, E.D., Schwertner, W.R., Kuthi, L.K., Masszi, R., Lakatos, B.K., Kovacs, A., and Becker, D. (2022). The Prognostic Value of Anemia in Patients with Preserved, Mildly Reduced and Recovered Ejection Fraction. Diagnostics, 12.","DOI":"10.3390\/diagnostics12020517"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e001012","DOI":"10.1136\/openhrt-2019-001012","article-title":"Iron deficiency in heart failure with preserved ejection fraction: A systematic review and meta-analysis","volume":"6","author":"Beale","year":"2019","journal-title":"Open Heart"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1056\/NEJMoa1214865","article-title":"Treatment of anemia with darbepoetin alfa in systolic heart failure","volume":"368","author":"Swedberg","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/ejhf.823","article-title":"Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: An individual patient data meta-analysis","volume":"20","author":"Anker","year":"2018","journal-title":"Eur. J. Heart Fail."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: A multicentre, double-blind, randomised, controlled trial","volume":"396","author":"Ponikowski","year":"2020","journal-title":"Lancet"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1001\/jama.2017.5427","article-title":"Effect of Oral Iron Repletion on Exercise Capacity in Patients with Heart Failure with Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial","volume":"317","author":"Lewis","year":"2017","journal-title":"JAMA"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1002\/ejhf.1865","article-title":"Depression and heart failure: The lonely comorbidity","volume":"22","author":"Sbolli","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s10741-017-9640-5","article-title":"Effects of cognitive behavioural therapy for depression in heart failure patients: A systematic review and meta-analysis","volume":"22","author":"Jeyanantham","year":"2017","journal-title":"Heart Fail. Rev."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.jchf.2020.06.010","article-title":"Associations between Depressive Symptoms and HFpEF-Related Outcomes","volume":"8","author":"Chandra","year":"2020","journal-title":"JACC Heart Fail."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1177\/2047487314526071","article-title":"Effects of exercise training on different quality of life dimensions in heart failure with preserved ejection fraction: The Ex-DHF-P trial","volume":"22","author":"Nolte","year":"2015","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","article-title":"The perindopril in elderly people with chronic heart failure (PEP-CHF) study","volume":"27","author":"Cleland","year":"2006","journal-title":"Eur. Heart J."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_99","first-page":"100451","article-title":"The progress and controversial of the use of beta blockers in patients with heart failure with a preserved ejection fraction","volume":"26","author":"Xu","year":"2020","journal-title":"Int. J. Cardiol. Heart Vasc."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jacc.2009.02.046","article-title":"Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with Heart Failure)","volume":"53","author":"Anker","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/eurjhf\/hfs141","article-title":"Effects of carvedilol on heart failure with preserved ejection fraction: The Japanese Diastolic Heart Failure Study (J-DHF)","volume":"15","author":"Yamamoto","year":"2013","journal-title":"Eur. J. Heart Fail."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","article-title":"Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: An individual patient-level analysis of double-blind randomized trials","volume":"39","author":"Cleland","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1161\/CIRCULATIONAHA.120.047643","article-title":"Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure with Preserved Ejection Fraction","volume":"142","author":"Lefkowitz","year":"2020","journal-title":"Circulation"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.119.044491","article-title":"Effects of Sacubitril-Valsartan versus Valsartan in Women Compared with Men with Heart Failure and Preserved Ejection Fraction: Insights from PARAGON-HF","volume":"141","author":"McMurray","year":"2020","journal-title":"Circulation"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure","volume":"141","author":"Solomon","year":"2020","journal-title":"Circulation"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jacc.2019.11.003","article-title":"Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril\/Valsartan Compared with Valsartan in HFpEF","volume":"75","author":"Vaduganathan","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.cardfail.2023.05.003","article-title":"Duration of Heart Failure with Preserved Ejection Fraction and Outcomes with Sacubitril\/Valsartan: Insights from the PARAGON-HF Trial","volume":"29","author":"Ostrominski","year":"2023","journal-title":"J. Card. Fail."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jchf.2021.04.009","article-title":"Integrating High-Sensitivity Troponin T and Sacubitril\/Valsartan Treatment in HFpEF: The PARAGON-HF Trial","volume":"9","author":"Gori","year":"2021","journal-title":"JACC Heart Fail."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.cardfail.2023.02.001","article-title":"Rationale, Design and Baseline Characteristics of the PARAGLIDE-HF Trial: Sacubitril\/Valsartan vs Valsartan in HFmrEF and HFpEF with a Worsening Heart Failure Event","volume":"29","author":"Mentz","year":"2023","journal-title":"J. Card. Fail."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1093\/eurheartj\/ehad344","article-title":"Sacubitril\/valsartan in heart failure with mildly reduced or preserved ejection fraction: A pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF","volume":"44","author":"Vaduganathan","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2459\/JCM.0000000000001411","article-title":"Sacubitril\/valsartan reduces cardiac decompensation in heart failure with preserved ejection fraction: A meta-analysis","volume":"24","author":"Basile","year":"2023","journal-title":"J. Cardiovasc. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.cardfail.2023.03.019","article-title":"The Effect of Sacubitril\/Valsartan on Left Ventricular Myocardial Deformation in Heart Failure with Preserved Ejection Fraction (PARAMOUNT trial)","volume":"29","author":"Lassen","year":"2023","journal-title":"J. Card. Fail."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1093\/eurheartj\/ehs124","article-title":"Phenotypic and pathophysiological heterogeneity in heart failure with preserved ejection fraction","volume":"33","author":"Shah","year":"2012","journal-title":"Eur. Heart J."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1001\/jamacardio.2023.0065","article-title":"Effect of Sacubitril\/Valsartan vs Valsartan on Left Atrial Volume in Patients with Pre-Heart Failure with Preserved Ejection Fraction: The PARABLE Randomized Clinical Trial","volume":"8","author":"Ledwidge","year":"2023","journal-title":"JAMA Cardiol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e010176","DOI":"10.1161\/CIRCHEARTFAILURE.122.010176","article-title":"Adoption of Sacubitril\/Valsartan among Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: The Get with The Guidelines-Heart Failure Registry","volume":"16","author":"Pierce","year":"2023","journal-title":"Circ. Heart Fail."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1001\/jama.2021.18463","article-title":"Effect of Sacubitril\/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients with Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial","volume":"326","author":"Pieske","year":"2021","journal-title":"JAMA"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2023.04.019","article-title":"Angiotensin-Neprilysin Inhibition in Patients with Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure","volume":"82","author":"Mentz","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cardfail.2022.02.010","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure","volume":"28","author":"Heidenreich","year":"2022","journal-title":"J. Card. Fail."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: The Aldo-DHF randomized controlled trial","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41569-023-00922-x","article-title":"Non-steroidal mineralocorticoid receptor antagonists in heart failure","volume":"20","author":"Filippatos","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s11886-022-01750-0","article-title":"Effects of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, on Cardiovascular Disease, Chronic Kidney Disease, and Blood Pressure","volume":"24","author":"Ravid","year":"2022","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1161\/CIRCULATIONAHA.120.051898","article-title":"Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes","volume":"143","author":"Filippatos","year":"2021","journal-title":"Circulation"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.mayocp.2020.11.006","article-title":"Loop Diuretic Use and Outcomes in Chronic Stable Heart Failure with Preserved Ejection Fraction-Reply","volume":"96","author":"Rao","year":"2021","journal-title":"Mayo Clin. Proc."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/S0002-9149(00)00795-5","article-title":"Furosemide withdrawal in elderly heart failure patients with preserved left ventricular systolic function","volume":"85","author":"Jansen","year":"2000","journal-title":"Am. J. Cardiol."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Parajuli, P., Lara-Garcia, O.E., Regmi, M.R., Skoza, W., Bhattarai, M., Kulkarni, A., and Robinson, R.L. (2020). Heart Failure Drug Class Effects on 30-Day Readmission Rates in Patients with Heart Failure with Preserved Ejection Fraction: A Retrospective Single Center Study. Medicines, 7.","DOI":"10.3390\/medicines7050030"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","article-title":"The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: A multicenter randomized trial","volume":"27","author":"Nassif","year":"2021","journal-title":"Nat. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1038\/s41591-022-01971-4","article-title":"Dapagliflozin across the range of ejection fraction in patients with heart failure: A patient-level, pooled meta-analysis of DAPA-HF and DELIVER","volume":"28","author":"Jhund","year":"2022","journal-title":"Nat. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1161\/CIRCULATIONAHA.121.057812","article-title":"Empagliflozin, Health Status, and Quality of Life in Patients with Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial","volume":"145","author":"Butler","year":"2022","journal-title":"Circulation"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41591-022-01703-8","article-title":"The SGLT2 inhibitor canagliflozin in heart failure: The CHIEF-HF remote, patient-centered randomized trial","volume":"28","author":"Spertus","year":"2022","journal-title":"Nat. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"e026590","DOI":"10.1136\/bmjopen-2018-026590","article-title":"The effect of luseogliflozin and alpha-glucosidase inhibitor on heart failure with preserved ejection fraction in diabetic patients: Rationale and design of the MUSCAT-HF randomised controlled trial","volume":"9","author":"Ejiri","year":"2019","journal-title":"BMJ Open"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1002\/ehf2.12707","article-title":"Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: A randomized trial (CANDLE)","volume":"7","author":"Tanaka","year":"2020","journal-title":"ESC Heart Fail."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/eurjhf\/hfq219","article-title":"Self-care management of heart failure: Practical recommendations from the Patient Care Committee of the Heart Failure Association of the European Society of Cardiology","volume":"13","author":"Lainscak","year":"2011","journal-title":"Eur. J. Heart Fail."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.hrtlng.2022.07.013","article-title":"What kind of patient education and self-care support do patients with heart failure receive, and by whom? Implementation of the ESC guidelines for heart failure in three European regions","volume":"57","author":"Baldewijns","year":"2023","journal-title":"Heart Lung"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"520","DOI":"10.4037\/ajcc2002.11.6.520","article-title":"Cognitive impairment in heart failure: Issues of measurement and etiology","volume":"11","author":"Riegel","year":"2002","journal-title":"Am. J. Crit. Care"},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Lee, S.J., and Kim, B.H. (2022). Development of Core Educational Content for Heart Failure Patients in Transition from Hospital to Home Care: A Delphi Study. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph19116550"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.acvd.2017.03.010","article-title":"Effectiveness of a patient education programme in heart failure with preserved ejection fraction: Results from the ODIN cohort study using propensity score matching","volume":"111","author":"Agrinier","year":"2018","journal-title":"Arch. Cardiovasc. Dis."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0735-1097(01)01699-0","article-title":"Randomized trial of an education and support intervention to prevent readmission of patients with heart failure","volume":"39","author":"Krumholz","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_148","first-page":"213","article-title":"Motivational interviewing to improve the self-care behaviors for patients with chronic heart failure: A randomized controlled trial","volume":"5","author":"Chen","year":"2018","journal-title":"Int. J. Nurs. Sci."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1460458221996409","DOI":"10.1177\/1460458221996409","article-title":"Effect of physician prescribed information on hospital readmission and death after discharge among patients with health failure: A randomized controlled trial","volume":"27","author":"Gavgani","year":"2021","journal-title":"Health Inform. J."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3233\/WOR-213491","article-title":"Symptom perception management education improves self-care in patients with heart failure","volume":"69","author":"Sousa","year":"2021","journal-title":"Work"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1001\/archinternmed.2007.83","article-title":"Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH)","volume":"168","author":"Jaarsma","year":"2008","journal-title":"Arch. Intern. Med."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1177\/0018578719889020","article-title":"Impact of Heart Failure Transitions of Care Program: A Prospective Study of Heart Failure Education and Patient Satisfaction","volume":"56","author":"Mills","year":"2021","journal-title":"Hosp. Pharm."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Athar, M.W., Record, J.D., Martire, C., Hellmann, D.B., and Ziegelstein, R.C. (2018). The Effect of a Personalized Approach to Patient Education on Heart Failure Self-Management. J. Pers. Med., 8.","DOI":"10.3390\/jpm8040039"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"e054956","DOI":"10.1136\/bmjopen-2021-054956","article-title":"Using Mobile Integrated Health and telehealth to support transitions of care among patients with heart failure (MIGHTy-Heart): Protocol for a pragmatic randomised controlled trial","volume":"12","author":"Daniels","year":"2022","journal-title":"BMJ Open"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/1357633X15625540","article-title":"The effectiveness of the use of consumer health information technology in patients with heart failure: A meta-analysis and narrative review of randomized controlled trials","volume":"23","author":"Or","year":"2017","journal-title":"J. Telemed. Telecare"},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Ca\u00f1on-Monta\u00f1ez, W., Duque-Cartagena, T., and Rodr\u00edguez-Acelas, A.L. (2021). Effect of Educational Interventions to Reduce Readmissions due to Heart Failure Decompensation in Adults: A Systematic Review and Meta-analysis. Investig. Educ. Enferm., 39.","DOI":"10.17533\/udea.iee.v39n2e05"},{"key":"ref_157","first-page":"28","article-title":"Information therapy: A new interest for HIM","volume":"80","year":"2009","journal-title":"J. AHIMA"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.pec.2020.01.007","article-title":"Effects of an educational intervention on heart failure knowledge, self-care behaviors, and health-related quality of life of patients with heart failure: Exploring the role of depression","volume":"103","author":"Hwang","year":"2020","journal-title":"Patient Educ. Couns."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.ijcard.2012.09.030","article-title":"Therapeutic patient education and all-cause mortality in patients with chronic heart failure: A propensity analysis","volume":"168","author":"Jourdain","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3109\/13814788.2010.527938","article-title":"The impact of a nurse-led care programme on events and physical and psychosocial parameters in patients with heart failure with preserved ejection fraction: A randomized clinical trial in primary care in Russia","volume":"16","author":"Andryukhin","year":"2010","journal-title":"Eur. J. Gen. Pract."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/5\/1375\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:06:19Z","timestamp":1760105179000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/5\/1375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,28]]},"references-count":160,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["jcm13051375"],"URL":"https:\/\/doi.org\/10.3390\/jcm13051375","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,28]]}}}